Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.40 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | COPS5 | Q92905 | 2/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.36 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20504181 | 0.83 | NPSR1 (0.43) | HCAR2HCAR3KDM4EALDH1A1NPSR1 | |
| SCHEMBL3109908 | 0.83 | HCAR2 (0.43) | HCAR2HCAR3COPS5GPR35 | |
| SCHEMBL1034370 | 0.82 | COPS5 (0.54) | HCAR2HCAR3ALDH1A1COPS5 | |
| SCHEMBL9643790 | 0.73 | GPR35 (0.41) | HCAR2HCAR3KDM4EALDH1A1NPSR1 | |
| SCHEMBL20503252 | 0.73 | ALDH1A1 (0.47) | KDM4EALDH1A1NPSR1CYP2C9SMN1; SMN2 | |
| SCHEMBL11308300 | 0.73 | ALDH1A1 (0.43) | KDM4EALDH1A1NPSR1CYP2C9TP53 | |
| SCHEMBL22774382 | 0.73 | L3MBTL1 (0.40) | HCAR2ALDH1A1COPS5 | |
| SCHEMBL20503273 | 0.72 | GPR35 (0.47) | KDM4EALDH1A1NPSR1CYP2C9SMN1; SMN2 | |
| SCHEMBL9643970 | 0.72 | GPR35 (0.43) | HCAR2KDM4EALDH1A1NPSR1GPR35 | |
| SCHEMBL28331464 | 0.72 | ALDH1A1 (0.50) | KDM4EALDH1A1TP53MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101874030-B | Pyrrolidines and piperidines as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD | 2012-11-14 | — | — | CN | disclosed |
| US-8288411-B2 | Pyrrolidines and piperidines as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-10-16 | — | — | US | disclosed |
| CN-101874030-A | Pyrrolidines and piperidines as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD | 2010-10-27 | — | — | CN | disclosed |
| US-20100197733-A1 | PYRROLIDINES AND PIPERIDINES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-08-05 | — | — | US | disclosed |
| EP-2207778-A2 | PYRROLIDINES AND PIPERIDINES AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2010-07-21 | — | — | EP | disclosed |
| WO-2009040730-A2 | PYRROLIDINES AND PIPERIDINES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197733-A1 | PYRROLIDINES AND PIPERIDINES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR1, HCRTR2, NPY1R | HCAR2 55/4885HCAR3 71/4885KDM4E 1763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.